Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation

Inflammation Research

Volumn 49, Issue 2, 2000, Pages 47-54

  De Keyser, F ^a   Van Damme, N ^a   De Vos, M ^a   Mielants, H ^a   Veys, E M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Crohn's disease; Immune modulation; Inflammatory bowel disease; Reactive arthritis; Spondyloarthropathy

Indexed keywords

AMINOSALICYLIC ACID; SALAZOSULFAPYRIDINE;

ANTIINFLAMMATORY ACTIVITY; COLON CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; ENTERITIS; HUMAN; IMMUNOMODULATION; REACTIVE ARTHRITIS; REVIEW; SACROILIAC JOINT; SPONDYLITIS; SPONDYLOARTHROPATHY; SYNOVITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL ADHESION MOLECULES; CYTOKINES; EXERCISE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; SPONDYLITIS;

EID: 0033995141     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050558     Document Type: Review

References (74)

1. [1] Wright V. Seronegative polyarthritis - a unified concept. Arthritis Rheum 1978; 21: 618-33.
2. [2] Amor B, Dougados M, Mijiyawa M. Critères de classification des spondyloarthropathies. Rev Rhum 1990; 57: 85-9.
3. [3] Bjarnason I, Hayllar J, McPherson A, Russell AS. Side-effects of non-steroidal antiinflammatory drugs on the small and large intestine. Gastroenterology 1993; 104: 1832-47.
4. [4] Kaufman HJ, Taubin HL. NSAID activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513-6.
5. [5] Langman MS, Morgan L, Worrall A. Use of antiinflammatory drugs by patients with small or large bowel perforation and haemorraghe. Brit Med J 1985; 290: 347-9.
6. [6] Morris AJ, Madhock R, Sturrock RD, Capell HA, MacKenzie JF. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 520.
7. [7] Hayllar J, Smith T, McPherson A, Price AB, Gumpel M, Bjarnason L. Non-steroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Arthritis Rheum 1994; 37: 1146-50.
8. [8] Bjarnason I, Peters TJ. Influence of antirheumatic drugs on gut permeability and on the gut associated lymphoid tissue. Baillière's Clinical Rheumatol 1996; 10: 165-76.
9. [9] Mielants H, Veys EM. The bowel and spondylarthritis : a clinical approach. In: The spondylarthritides, Calin A, Taurog JD, editors. New York: Oxford University Press, 1998: 129-57.
10. [10] De Keyser F, Elewaut D, De Vos M, De Vlam K, Cuvelier C, Mielants H, et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24: 785-813.11
11. [11] Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, et al. The evolution of the spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995; 22: 2266-72.
12. [12] De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110: 1696-703.
13. [13] Elewaut D, Granfors K, De Keyser F, Hoffman I, Veys E. Extra-intestinal manifestations of enteropathies: why are the joints involved? Rheumatol Eur 1997; 26: 18-23.
14. [14] Mielants H, De Keyser F, Veys EM. Enteropathic arthritis. In: Koopman W, editor. Arthritis and Allied Conditions - A Textbook of Rheumatology, XIV edition.
15. [15] Moll J. Inflammatory bowel disease. Clin Rheum Dis 1985; 11: 87-111.
16. [16] Mc Ewen C, Lingg C, Kirsner JB. Arthritis accompanying ulcerative colitis. Am J Med 1962; 33: 923-41.
17. [17] Greenstein AJ, Jarowitz HD, Scalar BD. The extra-intestinal manifestations of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55: 401-12.
18. [18] Summers RW, Switz DM, Sessions JT. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69.
19. [19] Baron JH, Connell PM, Lennard-Jones JE. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; 1: 1094-6.
20. [20] Dick AP, Grayson MJ, Carpenter RG. Controlled trials of Sulphasalazine in the treatment of ulcerative colitis. Gut 1964; 5: 437-42.
21. [21] Miesiewics JJ, Lennard-Jones JE, Connell AM. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; 1: 185-8.
22. [22] Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618-27.
23. [23] Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2004-12.
24. [24] Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-20.
25. [25] Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR Jr, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2021-7.
26. [26] Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892-5.
27. [27] Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995; 272: 399-406.
28. [28] Campieri M, Lanfranchi GA, Bazzochi G, et al. Treatment of ulcerative colitis with high dose 5-aminosalicylic acid enemas. Lancet 1981; 2: 270-271.
29. [29] Campieri M, Lanfranchi GA, Brignola C, et al. 5-Aminosalicylic acid for the treatment of inflammatory bowel disease [letter]. Gastroenterology 1985; 89: 701-3.
30. [30] Biddle WL, Greenberger NS, Swan JT, McPhee MS, Minner PB. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988; 94: 1075-9.
31. [31] Taggart AJ, Gardiner P, McEvoy FM, Hopkins R, Bird H. Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized controlled study. Arthritis Rheum 1996; 39: 1400-5.
32. [32] Thomson GT, McKibbon C, Inman RD. Mesalamine therapy in Reiter's syndrome. J Rheumatol 1994; 21: 570-2.
33. [33] Zwillich SH, Ritchlin CT. Olsalazine in Reiter's syndrome. J Rheumatol 1994; 21: 2169-70.
34. [34] Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
35. [35] Meyers S, Janowitz HD. Natural history of Crohn's disease. An analytic review of the placebo lesson. Gastroenterology 1984; 87: 1189-92.
36. [36] Granfors K, Jalkanen S, Lindberg AA, Maki-Ikola O, von Essen R, Lahesmaa-Rantala R, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet 1990; 335: 685-8.
37. [37] Granfors K, Jalkanen S, Von Essen R, Lahesmaa-Rantala R, Isomaki O, Pekkola-Heino K, et al. Yersinia antigens in synovial fluid cells from patients with reactive arthritis. N Engl J Med 1989; 320: 216-21.
38. [38] Leirisalo-Repo M. Therapeutic aspects of spondyloarthropathies -a review. Scand J Rheumatol 1998; 27: 323-8.
39. [39] Sieper J, Braun J. Treatment of reactive arthritis with antibiotics. Br J Rheumatol 1998; 37: 717-20.
40. [40] Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European cooperative Crohn's disease Study (ECCDS): results of drugs treatment. Gastroenterology 1984;86:249-66.
41. [41] Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407-14.
42. [42] Hamedani R, Feldman RD, Feagan BG. Drug development in inflammatory bowel disease: budesonide - a model of targeted therapy. Aliment Pharmacol Ther 1997; 11: 98-108.
43. [43] Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423-33.
44. [44] Vandeputte L, D'Haens G, Baert F, Rutgeerts P. Methotrexate in refractory Crohn's disease. Inflamm Bowel Dis 1999; 5: 11-5.
45. [45] Ostendorf B, Specker C, Schneider M. Methotrexate lacks efficacy in the treatment of severe ankylosing spondylitis compared with rheumatoid and psoriatic arthritis. J Clin Rheumatol 1998; 4: 129-36.
46. [46] Feagan BG, McDonald JWD, Rochon J, Laupacis A, Fedorak RN, Kinnear D, et al. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846-51.
47. [47] Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994; 91: 8562-6.
48. [48] Yin Z, Braun J, Neure L, Wu P, Liu L, Eggens U, et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum 1997; 40: 1788-99.
49. [49] Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999; 26: 16-21.
50. [50] Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999; 169: 175-94.
51. [51] Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
52. [52] Van Dullemen HM, Van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 10: 129-35.
53. [53] McCabe RP, Woody J, van Deventer S, Targan SR, Mayer L, van Hogezand R, et al. Multicenter trial of cA2 anti-TNF chimeric antibody in patients with active Crohn's disease. Gastroenterology 1996; 110: A962.
54. [54] Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
55. [55] Rutgeerts P, Haens GD, van Deventer SJH, Present DH, Mayer L, Hanauer SB, et al. Retreatment with anti-TNF-α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 1997; 112: A1078.
56. [56] Present D, Mayer L, van Deventer SJH, Rutgeerts P, Hanauer S, Targan SR, et al. Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn's disease: A multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 1997; 92: 1746.
57. [57] Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74.
58. [58] Grool TA, Van Dullemen H, Meenan J, Koster F, Ten Kate FJ, Lebeaut A. Anti-inflammatory effect of interleukin-10 in rabbit immune complex-induced colitis. Scand J Gastroenterol 1998; 33: 754-8.
59. [59] Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113: 383-9.
60. [60] Chaudepierre P, Rymer JC, Chevalier X. IL-10 plasma levels correlate with disease activity in spondyloarthropathy [letter]. J Rheumatol 1997; 24: 1659-61.
61. [61 ] Simon AK, Seipelt E, Wu P, Braun J, Sieper J. Analysis of cytokine profiles in synovial T cell clones from chlamydial reactivearthritis patients: Predominance of the Thl subset. Clin Exp Immunol 1993; 94: 122-6.
62. [62] Ritchlin C, Haas-Smith S, Looney J. Production, tissue distribution and function of IL-10 in psoriatic synovium [abstract]. Arthritis Rheum 1996; 39: S163.
63. [63] Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1388-97.
64. [64] Bank S. Recombinant human IL-11 in active Crohn's disease. Gastroenterology 1997; 112 (Suppl): A927.
65. [65] De Keyser F, Elewaut D, De Wever N, Bensbaho K, Cuvelier C. The gut associated addressins: lymphocytes homing in the gut. Baillière's Clinical Rheumatology. Gut Inflamm Rheumatol 1996; 10: 25-39.
66. [66] Buckley CD, Simmons DL. Cell adhesion: a new target for therapy. Mol Med Today 1997; 3: 449-56.
67. [67] Bernstein CN, Sargent M, Gallatin WM. Beta2 integrin/ICAM expression in Crohn's disease. Clin Immunol Immunopathol 1998; 86: 147-60.
68. [68] Kirman I, Nielsen OH. LFA-1 subunit expression in ulcerative colitis patients. Dig Dis Sci 1996; 41: 670-6.
69. [69] Bennett CF, Condon T, Grimm S, Chan H, Chiang MY. Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides. J Immunol 1994; 152: 3530-40.
70. [70] Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisnser DL, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-42.
71. [71] Erle DJ, Briskin MJ, Butcher EC. Expression and function of the MadCAM-1 receptor on human leukocytes. J Immunol 1994; 153: 517-28.
72. [72] Elewaut D, De Keyser F, Van den Bosch F, Lazarovits AI, De Vos M, Cuvelier C, et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998; 25: 1932-7.
73. [73] Podolsky K, Lobb R, King N, Benjamin CD, Pepinsky B, Sehgal P, et al. Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody. J Clin Invest 1993; 92: 372-80.
74. [74] Hesterberg PE, Winsor-Hine D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha4 beta7. Gastroenterology 1996; 111: 1373-80.